Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-040360
Filing Date
2019-11-05
Accepted
2019-11-05 16:06:31
Documents
58
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-10q_20190930.htm 10-Q 2111796
2 EX-31.1 fate-ex311_6.htm EX-31.1 9832
3 EX-32.1 fate-ex321_7.htm EX-32.1 4878
  Complete submission text file 0001564590-19-040360.txt   9193035

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT fate-20190930.xml EX-101.INS 2459402
5 XBRL TAXONOMY EXTENSION SCHEMA fate-20190930.xsd EX-101.SCH 58080
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fate-20190930_cal.xml EX-101.CAL 51912
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20190930_def.xml EX-101.DEF 215418
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20190930_lab.xml EX-101.LAB 465098
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20190930_pre.xml EX-101.PRE 351698
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 191193303
SIC: 2836 Biological Products, (No Diagnostic Substances)